Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
B. Routy,E. Le Chatelier,45 Authors,L. Zitvogel
2018 · DOI: 10.1126/science.aan3706
Science · 4,871 Citations
TLDR
It is found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition, and Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer.